Hyperkalaemia in Heart Failure

Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbiditie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Umar Ismail, Kiran Sidhu, Shelley Zieroth
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/9419a0cd11214729a55fb86549079483
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9419a0cd11214729a55fb86549079483
record_format	dspace
spelling	oai:doaj.org-article:9419a0cd11214729a55fb865490794832021-12-04T16:04:27ZHyperkalaemia in Heart Failure10.15420/cfr.2020.292057-75592057-7540https://doaj.org/article/9419a0cd11214729a55fb865490794832021-05-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2020.29https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.Umar IsmailKiran SidhuShelley ZierothRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 7, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Umar Ismail Kiran Sidhu Shelley Zieroth Hyperkalaemia in Heart Failure
description	Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin–angiotensin–aldosterone system (RAAS) inhibitors and angiotensin–neprilysin inhibitors being the cornerstone of medical therapy. Patients living with HF often have other comorbidities, such as diabetes and chronic kidney disease, which predispose to hyperkalaemia. Until now, we have not had any reliable or tolerable therapies for the treatment of hyperkalaemia to facilitate implementation or achievement of target doses of RAAS inhibition. Patiromer sorbitex calcium and sodium zirconium cyclosilicate are two novel potassium-binding resins that have shown promise in the management of patients predisposed to developing recurrent hyperkalaemia, and their use may allow for further optimisation of guideline directed medical therapy.
format	article
author	Umar Ismail Kiran Sidhu Shelley Zieroth
author_facet	Umar Ismail Kiran Sidhu Shelley Zieroth
author_sort	Umar Ismail
title	Hyperkalaemia in Heart Failure
title_short	Hyperkalaemia in Heart Failure
title_full	Hyperkalaemia in Heart Failure
title_fullStr	Hyperkalaemia in Heart Failure
title_full_unstemmed	Hyperkalaemia in Heart Failure
title_sort	hyperkalaemia in heart failure
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/9419a0cd11214729a55fb86549079483
work_keys_str_mv	AT umarismail hyperkalaemiainheartfailure AT kiransidhu hyperkalaemiainheartfailure AT shelleyzieroth hyperkalaemiainheartfailure
_version_	1718372687530688512

Hyperkalaemia in Heart Failure

Ejemplares similares